QUOTE AND NEWS
FiercePharma  Dec 8  Comment 
Even a megablockbuster launch isn't enough to save Novartis sales reps targeted for job cuts. The company is laying off 200 primary care sales folks in New Jersey as it rejigs its sales operation and prepares to launch LCZ696, a hotly anticipated...
Forbes  Dec 8  Comment 
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF (VEA), which added 9,515,916 units, or a 1.6% increase week over week.  Among...
FierceBiotech  Dec 8  Comment 
A new cancer treatment from Novartis and its partners at the University of Pennsylvania came through in another round of early studies, posting stellar results and burnishing the promise of therapies that train the immune system to bear down on...
Motley Fool  Dec 4  Comment 
Array Biopharma surges by a double-digit percentage for a reason that would normally cause most biotech stocks to plunge.
Market Intelligence Center  Dec 4  Comment 
Novartis AG (NVS) presents a trading opportunity that offers a 2.41% return in just 134 days. A covered call on Novartis AG at the $95.00 level expiring on Apr. '15 offers an assigned return rate of 2.41% or 6.58% annualized. This trade offers...
FierceBiotech  Dec 4  Comment 
Usually, when a biotech company loses a Big Pharma development partner, the executives wind up circling the wagons in a vain attempt to defend the value of their drug. But for Boulder, CO-based Array BioPharma and its backers, Novartis' exit from...
The Hindu Business Line  Dec 4  Comment 
Europe’s drug regulator says there is no proof that a flu vaccine for the elderly was linked to side effects, including deaths in Italy.Last week, Italy pulled two batches of Fluad, made by...
Benzinga  Dec 3  Comment 
Array BioPharma Inc. (NASDAQ: ARRY) today announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement...
FiercePharma  Dec 3  Comment 
An Italian regional court is upholding charges levied earlier this year against Roche and Novartis, fining the companies €180 million for manipulating sales of Lucentis, their drug for wet age-related macular degeneration.
Benzinga  Dec 2  Comment 
Morgan Stanley issued reports Tuesday for Novartis AG (ADR) (NYSE: NVS) and AstraZeneca plc (ADR) (NYSE: AZN), creating a possible pair trade. Analysts led by Nicolas Guyon-Gellin downgraded AstraZeneca from Equal-weight to Underweight and...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki